# Investigate Linaprazan Glurate/Linaprazan in Healthy Subjects

> **NCT05742984** · PHASE1 · COMPLETED · sponsor: **Cinclus Pharma Holding AB** · enrollment: 75 (actual)

## Conditions studied

- GERD

## Interventions

- **DRUG:** linaprazan glurate 25 mg QD
- **DRUG:** linaprazan glurate 50 mg QD
- **DRUG:** linaprazan glurate 75 mg QD
- **DRUG:** linaprazan glurate 25 mg BID
- **DRUG:** linaprazan glurate 50 mg BID
- **DRUG:** linaprazan glurate 75 mg BID

## Key facts

- **NCT ID:** NCT05742984
- **Lead sponsor:** Cinclus Pharma Holding AB
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-01-26
- **Primary completion:** 2023-03-24
- **Final completion:** 2023-04-13
- **Target enrollment:** 75 (ACTUAL)
- **Last updated:** 2025-05-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05742984

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05742984, "Investigate Linaprazan Glurate/Linaprazan in Healthy Subjects". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT05742984. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*